Skip to content

Debt-to-assets at other companies

Pfizer logo
PfizerPFE
0.3×0.0×
Amgen logo
AmgenAMGN
0.6×0.0×
Incyte logo
IncyteINCY
0.0×
Tango Therapeutics logo
Tango TherapeuticsTNGX
0.1×-0.1×
CG Oncology logo
CG OncologyCGON
0.0×
Scholar Rock logo
Scholar RockSRRK
0.4×+0.2×

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Calculated from Cogent Biosciences, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s debt-to-assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s debt-to-assets?
Cogent Biosciences, Inc. (COGT) reported debt-to-assets of 0× in Q1 2026.
How has Cogent Biosciences, Inc.'s debt-to-assets changed year-over-year?
Cogent Biosciences, Inc.'s debt-to-assets decreased by 71.6% year-over-year, from 0.1× to 0×.
What is the long-term trend for Cogent Biosciences, Inc.'s debt-to-assets?
Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s debt-to-assets has grown at a -4.0% compound annual growth rate (CAGR), from 0× to 0×.
What does debt-to-assets mean?
Total debt divided by total assets at the quarter end. Measures the share of the asset base financed by debt.